Recruiting PHASE2 INTERVENTIONAL 4-arm NCT07254429

COMPASS - COpenhagen MenoPAuSe Study (COMPASS)

Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial

Sponsor: Martin Blomberg Jensen

Conditions Bone Markers Menopausal Osteoporosis

Interventions Estradiol (E2) Placebo gel Sodium Chloride 0.9% Testosterone Triptorelin 11.25 mg

Updated 4 times since 2025 Last updated: Feb 27, 2026 Started: Oct 2, 2025 Primary completion: Dec 31, 2027 Completion: May 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bone Markers and Menopausal Osteoporosis and is currently actively recruiting participants. Martin Blomberg Jensen leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2

First recorded

Oct 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Martin Blomberg Jensen

Data source: Copenhagen University Hospital at Herlev

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herlev, Denmark